0001236215-21-000010.txt : 20210517 0001236215-21-000010.hdr.sgml : 20210517 20210517173455 ACCESSION NUMBER: 0001236215-21-000010 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210514 FILED AS OF DATE: 20210517 DATE AS OF CHANGE: 20210517 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Watson Robert Eugene CENTRAL INDEX KEY: 0001511858 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11889 FILM NUMBER: 21932744 MAIL ADDRESS: STREET 1: 245 N. HIGHLAND AVE NE STREET 2: SUITE 230-296 CITY: ATLANTA STATE: GA ZIP: 30307 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2021-05-14 0 0000725363 CEL SCI CORP CVM 0001511858 Watson Robert Eugene 245 N. HIGHLAND AVE NE SUITE 230-296 ATLANTA GA 30307 1 0 0 0 Options 20.61 2021-05-14 4 A 0 128000 0.01 A 2031-05-13 Common Stock 128000 506000 D Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share. The stock options vest 100% upon either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia, or (b) if the closing price of the Company's common stock exceeds $42.00 for one trading day. None of the options will be exercisable before May 13, 2022. Robert Watson 2021-05-17